No profile data available.
Delcath Systems, Inc. (DCTH) is a healthcare company in the IV treatment equipment industry, based in Queensbury, United States, with about 156 full-time employees.
It reported revenue of $85.23 million for fiscal year 2025, up 129.1% from fiscal year 2024, and net income of $2.70 million. United States was its largest region in fiscal year 2025, with 92% of revenue. Its market capitalization was $532.97 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Delcath Systems reported $85.23 million in revenue for fiscal year 2025, up 129.1% from $37.21 million in fiscal year 2024.
United States: 92% of revenue by region in fiscal year 2025, followed by Foreign (8%).
$532.97 million as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include Iradimed Corporation (IRMD), Beta Bionics, Inc. (BBNX), CorMedix Inc. (CRMD), TriSalus Life Sciences, Inc. (TLSI).